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Zinc is released from glutamatergic (zincergic) neuron terminals in the hippocampus, followed by the increase in Zn2+
concentration in the intracellular (cytosol) compartment, as well as that in the extracellular compartment. The increase in Zn2+
concentrationintheintracellularcompartmentduringsynapticexcitationismainlyduetoZn2+ inﬂuxthroughcalcium-permeable
channels and serves as Zn2+ signaling as well as the case in the extracellular compartment. Synaptic Zn2+ homeostasis is important
forglutamatesignalingandalteredundernumerouspathologicalprocessessuchasAlzheimer’sdisease.SynapticZn2+ homeostasis
might be altered in old age, and this alteration might be involved in the pathogenesis and progression of Alzheimer’s disease; Zinc
mayplayasakey-mediatingfactorinthepathophysiologyofAlzheimer’sdisease.ThispapersummarizestheroleofZn2+ signaling
in glutamate excitotoxicity, which is involved in Alzheimer’s disease, to understand the signiﬁcance of synaptic Zn2+ homeostasis
in the pathophysiology of Alzheimer’s disease.
1.Introduction
Over300proteinsrequirezincfortheirfunctionsinmicroor-
ganisms, plants, and animals. Zinc powerfully inﬂuences cell
division and diﬀerentiation [1]. Zinc is essential for brain
growth and its function [2, 3]. Zinc concentration in the
adult brain reaches approximately 200μM[ 4]. Extracellular
zinc concentration in the adult brain is estimated to be less
than 1μM[ 5]. Zinc concentration in the cerebrospinal ﬂuid
(CSF) is approximately 0.15μM[ 6], while that in the plasma
is approximately 15μM. Zinc transport from the plasma
to the cerebrospinal ﬂuid is strictly regulated by the brain-
barriersystem,thatis,theblood-CSFbarrier.Theblood-CSF
barrier, in addition to the blood-brain barrier, is involved
in zinc homeostasis in the brain [7, 8]. Zinc is relatively
concentrated in the hippocampus and amygdala [9, 10]. The
biologicalhalf-lifeofzincisrelativelylonginthesestwoareas
(hippocampus, 28 days; amygdala, 42 days). Zinc homeosta-
sisinthebrainiscloselyassociatedwithneurologicaldiseases
includingAlzheimer’sdisease[11–13]andmaybespatiotem-
porally altered in their pathogenesis and progression.
Approximately 90% of the total brain zinc exists as zinc
metalloproteins. The rest mainly exists in the presynaptic
vesicles and is histochemically reactive as revealed by Timm’s
sulﬁde-silver staining method [14]. Histochemically reactive
zinc is released along with neuronal activity; there is a large
number of evidence on zincergic neurons that sequester
zinc in the presynaptic vesicles and release it in a calcium-
and impulse-dependent manner [15–18]. In the rat brain,
Timm’s stain is hardly observed just after the birth, and
its intensity increases with brain development [19, 20],
indicating that histochemically reactive zinc is involved in
not only brain growth but also brain function. However,
impairment of spatial learning, memory, or sensorimotor
functions is not observed in zinc transporter-3-null mice,
which lack the histochemically reactive zinc in synaptic
vesicles [21]. Zinc transporter-3 is involved to zinc transport
into synaptic vesicles. Therefore, physiological signiﬁcance
of histochemically reactive zinc in neuronal activity is still
poorly understood.
The hippocampus plays an important role in learning,
memory, and recognition of novelty [22]. The hippocampus2 International Journal of Alzheimer’s Disease
receives major input from the entorhinal cortex via the
perforant pathway, the dentate granule cells project to the
CA3 pyramidal cells via the mossy ﬁbers, and the CA3
pyramidal cells project to the CA1 pyramidal cells via the
Schaﬀer collaterals. The three pathways are glutamatergic
(zincergic), and terminals of them are stained by Timm’s
method [23]. Zinc concentration in the presynaptic vesi-
cles is the highest in the giant boutons of hippocampal
mossy ﬁbers. All giant boutons of mossy ﬁbers contain
zinc in the presynaptic vesicles, while approximately 45%
of Schaﬀer collateral/commissural pathway is zinc-positive
[24]. It has been reported that histochemically reactive
zinc serves as an endogenous neuromodulator of several
important receptors including the α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA)/kainate receptor,
N-methyl-D-aspartate (NMDA) receptors, and γ-amino
b u t y r i ca c i d( G A B A )r e c e p t o r s[ 25, 26]. The zinc may par-
ticipate in synaptic plasticity such as long-term potentiation
(LTP) and long-term depression (LTD) that is believed as the
mechanism of learning and memory [27–29].
The exact chemical form of histochemically reactive zinc
is unknown. The zinc released in the extracellular space
is estimated to serve in free form (Zn2+)[ 30]. The basal
Zn2+ concentrations are extremely low in both the extra-
cellular (∼10−8 M) and intracellular (cytosol) (<10−9 M)
compartments [31, 32]. Zn2+ concentration increases in
both compartments by excitation of zincergic neurons [33]
and serves for signaling [34, 35]. However, the extracellu-
lar and intracellular concentrations of Zn2+ reached after
synaptic excitation are obscure. Other organelles such as
the mitochondria and the endoplasmic reticulum including
the cytoplasm may participate in the increase in cytosolic
Zn2+ [36–38]. The mechanisms on Zn2+ homeostasis in both
compartments remain to be clariﬁed [39, 40].
Zn2+ signaling is required for brain function, while
alteration of Zn2+ homeostasis may modify glutamate exci-
totoxicity, which is involved in Alzheimer’s disease. This
paper summarizes the role of Zn2+ signaling in glutamate
excitotoxicity to understand the signiﬁcance of zinc as a
key-mediating factor in the pathophysiology of Alzheimer’s
disease.
2. Modulation of GlutamateSignalingby Zinc
ZnAF-2 is a membrane-impermeable zinc indicator and has
al o wK d value of 2.7nM for zinc, and its ﬂuorescence is
minimally changed in the presence of calcium, magnesium,
cadmium, nickel, or other heavy metals [41]. ZnAF-
2 DA, a diacetylated form of ZnAF-2, is taken up by
cells and hydrolyzed to ZnAF-2, which cannot permeate
the cell membrane. These two indicators make possible
an observation of Zn2+ dynamics in extracellular and
intracellular compartments. Zn2+ released from zincergic
neuron terminals is immediately retaken up by the same
terminals during tetanic stimulation and also taken up into
postsynaptic neurons [33, 35]. Calcium cannels such as
calcium-permeable AMPA/kainate receptors are involved
in Zn2+ inﬂux during synaptic excitation [5, 31, 33, 35, 42]
(Figure 1). Because kainate receptors are abundantly
expressed in mossy ﬁbers, they might be involved in zinc
inﬂux into mossy ﬁber terminals [43].
Quinta-Ferreira and Matias [44, 45] report that Ca2+
inﬂux into mossy ﬁbers by tetanic stimulation is inhibited
by endogenous zinc. In the CA3 and CA1, furthermore,
Zn2+ releasedfromzincergicneuronterminalssuppressesthe
increase in Ca2+ inﬂux into the presynaptic terminals after
tetanic stimulation, followed by negative modulation of the
presynaptic activity (exocytosis) (Figure 2)[ 33, 35]. In an
experimentusingsynaptosomalfractionfromrathippocam-
pal CA3, Zn2+ inhibits glutamate release via activation of
presynaptic ATP-dependent potassium (KATP) channels [46].
Zn2+ released from zincergic neuron terminals may serve
for negative feedback mechanisms against glutamate release
in both the extracellular and intracellular compartments
(Figure 2).
3. Crosstalk of Zn2+ Signaling to Ca2+ Signaling
inGlutamateExcitotoxicity
In both the extracellular and the intracellular compartments,
it is possible that zinc signaling plays a neuroprotective role
against glutamate-induced excitotoxicity [46, 47]. Activation
of presynaptic kainate receptors is involved in the release
of zinc and glutamate from mossy ﬁbers [48, 49], and
astrocytes also release glutamate [50]. Loss of astrocyte
glutamate homeostasis is a prerequisite for the excitotoxic
cascade, a phenomenon that is becoming recognized in
an increasing number of neurological disorders [51]. The
signiﬁcanceofzincreleaseinexcessexcitationofmossyﬁbers
is examined by regional delivery of glutamate (1mM) to
the stratum lucidum, in which mossy ﬁbers exist. Zn2+ may
negatively modulate Ca2+ mobilization in CA3 pyramidal
cells under the delivery [52]. Intracellular Ca2+ mobilization
via group I metabotropic glutamate receptor activation can
be also negatively modulated by Zn2+ signaling in CA3
pyramidal cells [34]. These ﬁndings suggest that Zn2+can
protectively act on glutamate excitotoxicity via crosstalk to
Ca2+ signaling.
In contrast, excess of intracellular Zn2+ is potentially
neurotoxic as well as excess of intracellular Ca2+ [53–60]
(Figure 2). The origin of the toxic zinc is a matter of debate
and seems to be not only the extracellular compartment
but also the intracellular compartment [61]. The exact
borderline of intracellular Zn2+ level between physiological
regulation and pathological eﬀects remains poorly deﬁned as
discussedlater.Cˆ ot´ eetal.[62]reportthattheneurotoxicand
neuroprotective actions of Zn2+ depend on its concentration
and that this dual action is cell type speciﬁc. Lavoie et al. [63]
report that intracellular zinc chelator inﬂuences hippocam-
pal neuronal excitability in rats. Furthermore, chelation of
endogenous zinc by CaEDTA causes a signiﬁcant increase in
ischemic cell death in hippocampal slice cultures [46]. In an
invivomicrodialysisexperiment,theincreaseinextracellular
glutamate concentrationinduced with high 100mM KCl was
signiﬁcantly enhanced in the presence of 1mM CaEDTA in
both the control and zinc-deﬁcient rats [64]. These ﬁndings
indicate that Zn2+ released from zincergic neurons mayInternational Journal of Alzheimer’s Disease 3
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Figure 1: Changes in zinc signals in the extracellular and intracellular compartments in the hippocampal CA1 during tetanic stimulation.
(a) Hippocampal illustration and CA1 image with ZnAF-2. (b) High-frequency stimulation (HSF, 200Hz, 1s) was delivered to the Schaﬀer
collaterals in hippocampal slices stained with ZnAF-2 or ZnAF-2DA. The circle (around 10μmi nd i a m e t e r )s h o w ni nFigure 1(a) is a
representative example of the region of interest. The data represents the changed rate (%) in ﬂuorescent signals to the basal ﬂuorescent
signal before the stimulation, which is expressed as 100%. The red bar indicates the period of electrical stimulation. (c) Tetanic stimulation
(200Hz, 1s) was delivered to the Schaﬀer collaterals in hippocampal slices immersed in ACSF (control), 1mM CaEDTA in ACSF, or 10μM
CNQX in ACSF. The data represents the changed rate (%) in ﬂuorescent signal during tetanic stimulation to the basal ﬂuorescent signal
before the stimulation, which is expressed as 100%. ∗∗∗P<. 001, versus the basal level before the stimulation; ##P<. 01, ###P<. 001, versus
the control (stimulated in ACSF). This data is cited from the paper published by Journal of Neuroscience Research, 2007 [35].
reduce glutamate release under pathological condition and
protect hippocampal cells from the excitotoxicity (Figure 2).
4. DietaryZincDeﬁciency and
GlutamateExcitotoxicity
Extracellular glutamate concentration is estimated to be
around 2μM in the brain, while glutamate concentration
in the synaptic vesicles is markedly high (∼100mM) [65].
Excessive activation of glutamate receptors by excess of
extracellular glutamate leads to a number of deleterious
consequences, including impairment of calcium buﬀering,
generation of free radicals, activation of the mitochon-
drial permeability transition, and secondary excitotoxicity
[66, 67]. Glutamate excitotoxicity, a ﬁnal common pathway
for neuronal death, is observed in numerous pathological
processes such as stroke/ischemia, temporal lobe epilepsy,
Alzheimer’s disease, and amyotrophic lateral sclerosis [68–
70]. The hippocampus is susceptible to glutamate excito-
toxicity, is enriched with glucocorticoid receptors [71], and
is a major target of glucocorticoids. Glucocorticoids may
potentiate glutamate excitotoxicity, followed by the increase
in neuronal death [72].
Dietary zinc deﬁciency readily decreases serum zinc level
in mice and rats, while it increases serum corticosterone
level through the increased hypothalamic-pituitary-adrenal
(HPA) axis activity [73]. Brain zinc concentration is hardly
decreased by zinc deﬁciency, while both histochemically
reactive zinc and extracellular zinc in the brain are sus-
ceptible to chronic zinc deﬁciency [64, 74–76]( Figure 3).
Excitability of zincergic neurons is potentially changed in
cooperation with corticosterone under zinc deﬁciency [27].
Thus, the increased secretion of corticosterone might be4 International Journal of Alzheimer’s Disease
Zn2+
Ca2+ Ca2+
Zn2+
Glu
Signaling
Zn2+
Ca2+ Ca2+
Zn2+
Glu
Excitotoxicity
Function
Zn2+
Zn
Glu
Zn
Glu
GluR
Physiological CaC
Pathological
Neuron terminal
Postneuron
[Glu]
Figure 2: Zn2+ signaling and glutamate excitotoxicity. Zinc released
from zincergic neuron terminals is immediately taken up into
presynaptic and postsynaptic neurons through calcium-permeable
channels (CaC and GluR). In presynaptic neurons, zinc negatively
modulates exocytosis. The negative modulation by zinc may
protectively serve for postsynaptic neurons under pathological
conditions that are linked with glutamate excitotoxicity.
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Figure 3: Histochemically reactive zinc level and its relation to
the pathogenesis of Alzheimer’s disease. Zinc deﬁciency can reduce
histochemically reactive zinc levels, which are estimated to be
susceptible to aging. Zinc deﬁciency, as well as aging, seems to be
a risk factor for Alzheimer’s disease.
associated with the decrease in histochemically reactive zinc
and extracellular zinc under zinc deﬁciency. The increase in
extracellular glutamate induced by 100mM KCl is poten-
tiated under zinc deﬁciency [64, 76]. Kainate and NMDA-
induced seizures are potentiated in young mice and rats after
4-week zinc deprivation, which decreases histochemically
reactive zinc [74, 77], and hippocampal cell death, which
is induced by treatment with kainate, is increased under
zinc deﬁciency [78]. These ﬁndings suggest that endogenous
zinc, especially histochemically reactive zinc, has a protective
action against glutamate excitotoxicity. The neurological
symptoms associated with glutamate excitotoxicity may be
aggravated by zinc deﬁciency.
Neuritic plaques, a pathological hallmark of Alzheimer’s
disease, are composed of β-amyloid that is precipitated
by zinc released from zincergic neurons [79–81]. Gluta-
mate excitotoxicity is associated with pathophysiology of
Alzheimer’s disease [67]. Glutamatergic signaling is com-
promised by β-amyloid-induced modulation of synaptic
glutamatereceptorsinspeciﬁcbrainregions,parallelingearly
cognitive deﬁcits [82]. Dietary zinc deﬁciency signiﬁcantly
increases total plaque volume in APP/PS1 mice, a transgenic
mouse model of Alzheimer’s disease, suggesting that zinc
deﬁciency is a risk factor for Alzheimer’s disease [83].
Interestingly, no obvious changes in histochemically reactive
zinc levels are observed in zinc-deﬁcient APP/PS1 mice.
It is possible that the HPA axis activity in APP/PS1 mice
is potentiated by zinc deﬁciency, like the case of normal
mice and rats. Serum glucocorticoids are associated with the
clearance of amyloid-beta peptide [84]. Thus, it seems to be
importanttostudytheparticipationofglucocorticoidsinthe
β-amyloid plaque formation and degradation.
5.ZincHomeostasis and Glutamate
Excitotoxicity in Old Age
Zinc concentration in the brain remains constant in aged
animals [85] and humans [4], whereas serum zinc level is
signiﬁcantly lower in aged animals than in young animals
[86] and decreases with age in humans [87]. Histochemically
reactive zinc levels are also lower in aged animals than
in adult animals [88, 89]. Zinc transporter-3 expression,
which is correlated with histochemically reactive zinc levels,
is decreased with aging [90]. Thus, it is possible that
histochemically reactive zinc levels are reduced in normal
aging in humans [12, 90]( Figure 3). On the other hand,
serum glucocorticoid concentration is signiﬁcantly higher in
aged animals [91]. The selective increase in the nocturnal
levels of cortisol is observed in aged humans [92]. The
increase in serum glucocorticoid level elicits some common
changes in both aging and zinc deﬁciency. In addition to
the decrease in serum zinc, the increase in the basal levels
of intracellular Ca2+ and modiﬁcation of Ca2+ signaling
is observed in both aged [93, 94] and zinc-deﬁcient [73,
77, 95] animals. It is likely that glucocorticoids inﬂuence
the dynamics of both zinc signal and calcium signal and
that the increased glucocorticoid secretion is associated
with dysfunctions in zinc deﬁciency and aging that may
increase the risk of diseases [28]. Aged animals and human
might be more susceptible to glutamate excitotoxicity that is
potentiated in zinc-deﬁcient animals.
Insulin-degrading enzyme is a candidate protease in the
clearance of amyloid-beta peptide from the brain and its
levelsaredecreasedinAlzheimer’sdisease.Insulin-degrading
enzyme activity is known to be inhibited by glucocorticoid.
Serum cortisol is associated with the clearance of amyloid-
beta peptide [81] and the progression in subjects with
Alzheimer-type dementia [96, 97]. Correlations have been
reported between increases in HPA system activity and
dementia severity or hippocampal volume loss in individuals
with probable Alzheimer’s disease [96]. On the other hand,
serum zinc is decreased in progression of Alzheimer’s
disease [98]. Because zinc participates in amyloid-beta
plaque deposition [79–81, 99], this metal may play as a
key-mediating factor in the pathophysiology of Alzheimer’s
disease [100, 101]. Adlard et al. [90] report that cognitive
loss is observed in 6-month-old zinc transporter-3-null
mice, but not in 3-month-old zinc transporter-3-null mice.
Cognitive impairment is age-dependent in zinc transporter-
3-null mice, suggesting that long-term lack of synaptic zinc
is implicated in the pathology leading to Alzheimer’s diseaseInternational Journal of Alzheimer’s Disease 5
(Figure 3). Because zinc transporter-3 expression is reduced
in the brain with Alzheimer’s disease [90], it is possible that
histochemical reactive zinc level is reduced in progression of
Alzheimer’s disease and that this reduction participates in
itspathophysiology.Incontrast,histochemicallyreactivezinc
levelsarenotsigniﬁcantlychangedinzinc-deﬁcientAPP/PS1
mice as described above [83] .C o g n i t i v el o s si sp o t e n t i a l l y
observed prior to the decrease in histochemically reactive
zinc in zinc-deﬁcient rats [102]. Judging from these data, it
is likely that the increase in HPA axis activity participates
in the pathogenesis and progression of Alzheimer’s disease
(Figure 3). This increase might be associated with the
decrease in histochemically reactive zinc levels.
The basal (resting) level of histochemical reactive
zinc/Zn2+ is estimated to be pico- to nanomolar in the
cytosolic compartment (8.1 < −log[Zn
2+]“free” < 10) [103–
105]. The synaptic vesicles serve as a large pool of histo-
chemical reactive zinc in zincergic neurons. Other organelles
such as the mitochondria and the endoplasmic reticulum
might generally serve as the pool of histochemical reactive
zinc in neurons and glia cells [36, 106]. Metallothioneins
are also pools of Zn2+ [37, 38, 107]. On the other hand,
extracellular zinc concentration after tetanic stimulation is
e s t i m a t e dt or a n g eb e t w e e n1 0a n d1 0 0 μM, because the
low-aﬃnity site (IC50 ≈ 20μMa t−40mV) of NMDA
receptors is bound by zinc as an NMDA receptor blocker
[108]. Hippocampal LTP is multifunctionally modulated
in the presence of 5μMZ n C l 2 [43, 109–111], suggesting
that the concentration of endogenous zinc reaches very low
micromolarconcentrationsintheextracellularcompartment
during the LTP induction. Judging from this estimation, it is
possible that zinc signal transiently increases to more than
100 times of the basal level in the cytosolic compartment.
Zn2+ might potentially reach submicromolar concentrations
(−log[Zn
2+]“free” < 6) under pathological conditions [105].
In conclusion, the analysis on the relationship between
Zn2+ dynamicsandglutamatergic(zincergic)neuronactivity
in the brain in process of aging may be useful to ﬁnd out
the strategy to prevent neurodegenerative disorders such as
Alzheimer’s disease [112].
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